Antipsychotic medications, historically called major tranquilizers or neuroleptics, form the backbone of pharmacological management for severe psychiatric disorders characterized by psychosis, such as schizophrenia and bipolar mania. These agents help patients regain contact with reality by reducing hallucinations, delusions, and disorganized thinking.
Pharmacologists broadly divide these medications into two distinct groups based on their chemical structure, receptor-binding profiles, and side effect tendencies:
The therapeutic efficacy of antipsychotics hinges primarily on their interaction with neurotransmitter receptors in the brain, most notably dopamine.
First-generation antipsychotics are potent antagonists of central dopamine D2 receptors. Common examples include haloperidol, chlorpromazine, and fluphenazine. While highly effective at managing acute psychotic agitation and positive symptoms, their lack of receptor selectivity often leads to significant neurological side effects.
Because they block dopamine uniformly across all brain pathways, they frequently induce movement disturbances and elevate prolactin levels. Chlorpromazine tends to cause more sedation and blood pressure drops, whereas haloperidol carries a high potency for extrapyramidal reactions.
Second-generation antipsychotics revolutionized mental health care by offering effective psychosis management with a reduced incidence of movement disorders. Frequently prescribed agents include clozapine, olanzapine, risperidone, quetiapine, and aripiprazole.
These drugs combine dopamine D2 and serotonin 5-HT2A antagonism. Although they spare patients many extrapyramidal symptoms, they introduce a distinct metabolic burden. Nurses must monitor for significant weight gain, dyslipidemia, insulin resistance, and new-onset diabetes mellitus, particularly with clozapine and olanzapine.
Blocking dopamine pathways outside the therapeutic target zones generates several distinct neurological movement disorders collectively known as extrapyramidal symptoms (EPS).
| EPS Type | Onset Timeframe | Clinical Presentation |
|---|---|---|
| Acute Dystonia | Hours to days | Severe muscle spasms of the neck, jaw, and tongue |
| Akathisia | Days to weeks | Inner restlessness, inability to sit still |
| Pseudoparkinsonism | Weeks | Resting tremor, rigidity, shuffling gait, drooling |
| Tardive Dyskinesia | Months to years | Involuntary choreoathetoid movements of the face and tongue |
Beyond EPS, nurses should watch for anticholinergic effects (dry mouth, blurred vision, constipation, urinary retention), sedation, and orthostatic hypotension resulting from alpha-adrenergic blockade.
Neuroleptic malignant syndrome (NMS) is a rare, unpredictable, but life-threatening medical emergency associated with the use of antipsychotic medications. It can develop at any point during therapy, though it most often appears shortly after initiation or following a dosage increase.
Classic clinical manifestations include extreme hyperthermia (often exceeding 40°C), severe lead-pipe muscle rigidity, altered mental status, and autonomic instability demonstrated by labile blood pressure, tachycardia, and profuse diaphoresis.
Immediate nursing and medical interventions:
Comprehensive nursing care for patients prescribed antipsychotics requires vigilant monitoring for both therapeutic efficacy and adverse reactions. Nurses must establish baseline assessments before drug administration and maintain consistent surveillance throughout the treatment course.
Monitoring protocols include regular checks of blood pressure for orthostatic changes, tracking body weight and waist circumference for metabolic shifts, and assessing for early signs of movement disorders using standardized rating scales like the Abnormal Involuntary Movement Scale (AIMS). Patient education is equally critical, emphasizing the importance of adherence, avoiding abrupt cessation to prevent withdrawal psychosis, and recognizing when to report dangerous symptoms like high fever or severe sore throat.